GlaxoSmithKline

GlaxoSmithKline reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2022 at 714 Kt (-126 /-15% y-o-y). Also positively, carbon intensity decreased to 18 t (-2 /-10.1% y-o-y).

GlaxoSmithKline's Scope 3 emissions tumbled to 8,624 Kt (-4,832 /-35.9% y-o-y). This is a higher rate of decline than over the period since 4Q'15 (-10.5% CAGR).

The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -89 Kt per annum over the period of FY2023 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Also, the company commits to reducing all Scopes by 80% by 2030 from a base year 2020, which translates into the estimated reduction of -733 Kt per annum over the period of FY2022 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

GlaxoSmithKline also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. GlaxoSmithKline commits to reduce absolute scope 1 and 2 GHG emissions 34% by 2025 from a 2017 base year. GSK also commits to reduce absolute scope 3 GHG emissions 16% by 2030 from a 2017 base year.